Skip to main content
NewslettersWatchlist

Aequus Pharmaceuticals Inc(AQS-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.005
Day High0.005
Open:0.005
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Aequus Pharmaceuticals Inc

Select a category then submit the form to load news
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Drug Manufacturers Industry Stocks (AQS)
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Drug Manufacturers Industry Stocks (AQS)
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Drug Manufacturers Industry Stocks (AQS)
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (AQS)
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Drug Manufacturers Industry Stocks (AQS)
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (AQS)
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (AQS)
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (AQS)
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 25 Undervalued TSX Venture Exchange Stocks (AQS)
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Drug Manufacturers Industry Stocks (AQS)
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (AQS)
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Drug Manufacturers Industry Stocks (AQS)
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (AQS)
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (AQS)
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (AQS)
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Growth Stocks on TSX-V (AQS)
AI-generated - The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Drug Manufacturers Industry Stocks (AQS)
GlobeNewswire
Aequus Reports Second Quarter 2023 Financial Highlights and General Update
GlobeNewswire
Aequus Announces Zimed PF Now Available in Canada
GlobeNewswire
Aequus Announces Zimed PF Website Launch
GlobeNewswire
Aequus Pharmaceutical Canada Announces a Pause in Sales of Evolve Intensive Eyedrops and Gel in Canada
GlobeNewswire
Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%)
The Globe and Mail
Aequus Pharmaceuticals: Top 10 Undervalued Drug Manufacturers Industry Stocks (AQS)
Globe Newswire
Press Release for Early Warning Report Regarding Aequus Pharmaceuticals Inc.
Globe Newswire
Aequus Resumes Trading on TSX Venture Exchange
Globe Newswire
Aequus Signs Exclusive Distribution Agreement with SCOPE Ophthalmics for Canadian Distribution Rights of Dry Eye Products
Globe Newswire
Aequus Provides General Update and Reports Record 2021 Financial Results
Globe Newswire
Aequus Provides Update on Delay in Filing Annual Financial Statements
Globe Newswire
Aequus Provides Update on Delay in Filing Annual Financial Statements
Globe Newswire
Aequus Provides Update on Delay in Filing Annual Financial Statements
Globe Newswire
Aequus Announces Delay in Filing Annual Financial Statements
Globe Newswire
Aequus Announces Short Term Loan

Profile

Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products namely Tacrolimus IR and Vistitan.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2025.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2025 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.